Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Roundhill GLP-1 & Weight Loss ETF (NQ: OZEM )

24.84 -0.22 (-0.88%)
Official Closing Price Updated: 4:15 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Roundhill GLP-1 & Weight Loss ETF

Eli Lilly's Blockbuster Obesity Drugs Miss Sales Estimates Again, But Investors Cheer Q4 Earnings Beat
Older diabetes medicines outperformed expectations, helping offset the shortfall in Lilly’s newer treatments. 
Via Stocktwits
Eli Lilly Gets Wall Street Backing After Tuesday’s Turmoil, Stock Rises Premarket As Retail Stays Bullish
JPMorgan's Chris Schott reportedly called the stock dip following the Q4 sales miss a buying opportunity. 
Via Stocktwits
Topics Earnings
Exposures Financial
Eli Lilly Stock Faces Worst Day In Nearly 4 Years On Q4 Weight-Loss Drug Sales Miss, But Retail Bullish On 2025 Projections
The pharma giant expects continued growth for Mounjaro and Zepbound this year, supported by expanded manufacturing capacity and new market launches. 
Via Stocktwits
Topics Earnings
Exposures Financial
Eli Lilly Stock Soars 34.42% YTD: A $1000 Investment Outpaces Returns From These ETFs Holding Mounjaro-Maker Shares
Recently, the company announced a massive $15 billion share buyback plan and a 15% dividend increase. 
Via Benzinga
Topics ETFs
EXCLUSIVE: Weight-Loss Duopoly Breaks As Eli Lilly, Novo Plummet; 'Market Won't Be Dominated By Just 2 Players'
Eli Lilly and Novo Nordisk face selloff as new weight-loss drugs threaten dominance. Shares of both companies drop significantly, highlighting need for diversification in this industry. 
Via Benzinga
ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential
New ETFs focusing on weight-loss drugs have launched. However, industry observers caution about their long-term prospects and the concentrated risks associated with these investments. 
Via Benzinga
Topics ETFs
New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk
New OZEM ETF offers investors exposure to weight-loss sector through top pharmaceutical companies Eli Lilly and Novo Nordisk, with potential for high growth but also risks. 
Via Benzinga
Topics ETFs
Tesla (TSLA) Stock Drops as Glass Lewis Urges Against Elon Musk’s Pay Package
Tesla stock is down on Tuesday as advisory firm Glass Lewis recommends TSLA shareholders vote against a massive pay package for Elon Musk. 
Via InvestorPlace
Campbell Soup Layoffs 2024: What to Know About New Campbell Job Cuts
Campbell Soup layoffs are coming for 415 workers as the company plans to close down one factory and shift operations at others. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF
As weight loss drugs are gaining popularity Roundhill GLP 1 And Weight Loss ETF (OZEM) has launched as anew way to invest in them. 
Via InvestorPlace
Topics ETFs
South Park Took On Crypto, AI Previously: Animated Comedy Targets Weight-Loss Drug Ozempic Next
Weight loss drugs get the new parody treatment in a "South Park" streaming special. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." 
Via Benzinga
Topics ETFs
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.